Equillium (EQ) FCF Margin (2023 - 2024)
Equillium (EQ) posted quarterly FCF Margin of 75.2% for Q4 2024, down 1333.0% year-over-year from 6.1% in Q1 2024, and down 19.44% quarter-over-quarter from 62.96% in Q3 2024.
Equillium (EQ) FCF Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported FCF Margin for 2 consecutive years, with 75.2% the latest figure, recorded in Q4 2024.
- In Q4 2024, FCF Margin fell 1333.0% year-over-year to 75.2%; the TTM figure through Sep 2025 stood at 521.86% (down 47502.0% YoY), while the FY2024 annual figure was 46.5%, up 1400.0% from the prior year.
- FCF Margin eased to 75.2% in Q4 2024 per EQ's latest filing, from 62.96% in the prior quarter.
- Across five years, FCF Margin topped out at 4.82% in Q2 2024 and bottomed at 90.04% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -75.20% |
| Sep 30, 2024 | -62.96% |
| Jun 30, 2024 | 4.82% |
| Mar 31, 2024 | -82.51% |
| Dec 31, 2023 | -61.87% |
| Sep 30, 2023 | -21.52% |
| Jun 30, 2023 | -68.12% |
| Mar 31, 2023 | -90.04% |